Capricor places DMD trial on hold

Capricor Therapeutics Inc. (NASDAQ:CAPR) placed a hold on the Phase II HOPE-2 trial of IV CAP-1002 for Duchenne muscular dystrophy (DMD) to investigate a severe allergic reaction that occurred in a patient during CAP-1002 infusion. Capricor, which disclosed the hold in an SEC filing, said it is working with FDA on a mitigation plan.

The double-blind, U.S. trial is slated to enroll about 84 non-ambulatory and ambulatory DMD patients to receive placebo or CAP-1002 every three months for 12 months. The primary endpoint will assess change in elbow dimension of Performance of the Upper Limb at month 12...